

## Supporting Information

### Co-delivery of icariside II and doxorubicin by self-assembled carrier-free nanofibers for anti-lung cancer therapy

Yishun Yang,<sup>\*a</sup> Yue Ding<sup>a</sup> and Tong Zhang<sup>\*abc</sup>

<sup>a</sup> Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

<sup>b</sup> School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

<sup>c</sup> State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

\* Corresponding authors: shun-105@hotmail.com; zhangtdmj@hotmail.com

Table S1 Median-effect parameters ( $D_m$ ) of combination therapy of ICAII and DOX against A549 cells

Sampe	$D_m$ (μM)		m	Correlation coefficient
	DOX (μM)	ICAIID (μM)		
DOX (μM)	3.98	—	5.23625	0.88523
ICAIID (μM)	—	39.62	5.02692	0.8556
15:1	0.47	7.09	1.36593	0.93815
ICAIID:DOX (m:m)	10:1	0.41	1.07275	0.98491
	5:1	0.39	0.86987	0.9063
	2.5:1	0.62	0.8135	0.91896

Note: The  $IC_{50}$  and  $D_m$  value of combination of ICAII and DOX group was calculated according to the concentration of DOX.

Table S2 Experimental data of combination therapy of ICAII and DOX against A549 cells

ICAIID:DOX (m:m)	DOX (μM)	ICAIID (μM)	Inhibition rate (%)	CI
15:1	0.0625	0.9375	10.34	0.060
	0.125	1.875	8.95	0.124
	0.25	3.75	15.99	0.218
	0.5	7.5	71.83	0.262
	1	15	66.17	0.552
10:1	0.0625	0.625	13.21	0.045
	0.125	1.25	18.66	0.084
	0.25	2.5	31.04	0.147
	0.5	5	64.85	0.223
	1	10	70.72	0.424
5:1	0.0625	0.3125	11.89	0.035
	0.125	0.625	23.66	0.059
	0.25	1.25	51.99	0.093
	0.5	2.5	73.96	0.154
	1	5	60.51	0.347
2.5:1	0.125	0.3125	16.46	0.054
	0.25	0.625	27.32	0.095
	0.5	1.25	65.53	0.139
	1	2.5	63.74	0.282
	2	5	63.61	0.565